Ned Pagliarulo is the Lead Editor at BioPharmaDive, where he covers the latest developments in the biopharmaceutical industry. With a focus on providing in-depth analysis and breaking news, Ned's articles explore topics such as drug approvals, mergers and acquisitions, clinical trials, and advancements in gene editing and therapy.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
International
Ned Pagliarulo's coverage predominantly focuses on the healthcare and pharmaceutical industries, with a substantial emphasis on industry-specific announcements and data citations. He would likely be interested in receiving pitches focused on breaking news related to pharmaceutical companies, drug development updates, FDA approvals, and biotech company developments.
Given Ned’s focus on press releases and data citations, he may be particularly receptive to pitches that provide exclusive access to newly released data or insights into industry trends. Experts who can offer unique perspectives based on their experience within the pharmaceutical or biotechnology sectors are also likely to capture his attention.
Since Ned does not have a specific geographic focus mentioned, it is important for potential sources to ensure that their pitches are relevant from a global perspective rather than being limited by location-specific details.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Ned Pagliarulo
Sales of Entresto and Cosentyx grew faster in the first quarter than analysts anticipated, helping drive the quarterly beat and raise.
An expanded partnership with OpenAI is helping Moderna embed custom-built AI chatbots in a wide range of research and business processes.
The layoffs will impact some 2,200 employees, the company said, as it repositions its business ahead of looming patent expirations for top-selling products.
By: Ned Pagliarulo
The company will soon start a Phase 1/2 study of its treatment for chronic granulomatous disease, a milestone for the search-and-replace gene editing technology.
Supply continues to be tight, however, and the company anticipates further sales growth to be limited by how quickly it can bring on additional production capacity.
By: Ned Pagliarulo
Sales of the transthyretin amyloidosis treatment widely beat Wall Street forecasts in the first quarter. The company aims to extend its patent exclusivity.
The company, BridgeBio Oncology Therapeutics, has one drug in the clinic and hopes to soon advance two other candidates.
Conversations at this year's J.P. Morgan Healthcare Conference led to a $1 billion buyout that Mariana's CEO described as a "perfect marriage."
Weeks after a safety setback derailed its lead candidate, the company has treated the first participant in a trial of its heart disease treatment Verve-102.
The company is discontinuing an array of early drug programs, including several in oncology, as it prioritizes investment in six late-stage assets.
(833) 317-6278 
